CyaA toxin translocation across host cell plasma membrane requires hijacking of calmodulin.

Abstract

Bordetella pertussis, the causative agent of whooping cough, secretes an adenylate cyclase toxin (CyaA, 1706 residues) that plays an essential role in the early stages of respiratory tract colonization of humans. After its secretion, CyaA intoxicates human cells via a direct translocation of its catalytic domain (ACD, 1-364) across the plasma membrane. Once in the cytosol, ACD binds to calmodulin and catalyses high amounts of cAMP, leading to cell death. Our results illustrate how the structural flexibility of CyaA is essential for its secretion, its folding, its translocation across plasma membrane and its enzymatic activity leading to cell intoxication. All of these steps involve disorder-to-order structural transitions that are finely tuned to the environmental conditions that CyaA successively experiences along its journey from the bacterium to the eukaryotic cell cytoplasm. Here, we focus on our recent results on ACD translocation across target cell membranes. The CyaA translocation region (TR, 365-520) contains a segment, P454 (residues 454-484), which exhibits membrane-active properties related to antimicrobial peptides. We show that P454 can translocate across membranes and interact with endogenous calmodulin. Structural and biophysical analyses reveal the key residues of P454 involved in membrane destabilization and calmodulin binding. Mutational analysis demonstrates that these residues play a crucial role in ACD translocation into target cells. We propose that after CyaA binding to target cells, the P454 segment destabilizes the plasma membrane, translocates across the lipid bilayer and binds calmodulin. Trapping of CyaA by the CaM:P454 interaction in the cytosol may assist the entry of ACD by converting the stochastic motion of the polypeptide chain through the membrane into an efficient vectorial chain translocation into host cells. These data open new avenues for biotechnological applications using CyaA as antigen delivery vehicle.